|
|
Volumn 100, Issue 9, 2016, Pages e50-e51
|
|
Updated manufacturer and European medicines agency recommendations on the use of mycophenolate acid: Balancing the risks for male allograft recipients
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CYCLOSPORIN;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
MYCOPHENOLATE MOFETIL;
TACROLIMUS;
IMMUNOSUPPRESSIVE AGENT;
MYCOPHENOLIC ACID;
ACUTE GRAFT REJECTION;
ALLOGRAFT;
CONDOM;
CONGENITAL DISORDER;
CONTRACEPTION;
DRUG WITHDRAWAL;
EMBRYOPATHY;
FEMALE FERTILITY;
GRAFT FAILURE;
GRAFT RECIPIENT;
HEALTH HAZARD;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
IN VITRO FERTILIZATION;
INCIDENCE;
INFERTILITY THERAPY;
KIDNEY TRANSPLANTATION;
LETTER;
MALE;
MALE ALLOGRAFT RECIPIENT;
MALE FERTILITY;
MALE INFERTILITY;
OVUM;
OVUM QUALITY;
PRACTICE GUIDELINE;
PREGNANCY;
PREMATURITY;
PRIORITY JOURNAL;
SPERM QUALITY;
SPONTANEOUS ABORTION;
SYSTEMATIC REVIEW;
DRUG APPROVAL;
DRUG INDUCED MALFORMATION;
DRUG INDUSTRY;
FEMALE;
GOVERNMENT;
LEGISLATION AND JURISPRUDENCE;
ORGAN TRANSPLANTATION;
PATIENT SAFETY;
PROCEDURES;
PRODUCT SAFETY;
RISK ASSESSMENT;
RISK FACTOR;
SEX FACTOR;
ABNORMALITIES, DRUG-INDUCED;
ALLOGRAFTS;
CONSUMER PRODUCT SAFETY;
DRUG APPROVAL;
DRUG INDUSTRY;
FEMALE;
GOVERNMENT AGENCIES;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MALE;
MYCOPHENOLIC ACID;
ORGAN TRANSPLANTATION;
PATIENT SAFETY;
PREGNANCY;
RISK ASSESSMENT;
RISK FACTORS;
SEX FACTORS;
|
|
EID: 84983781421
PISSN: 00411337
EISSN: None
Source Type: Journal
DOI: 10.1097/TP.0000000000001342 Document Type: Letter |
|
Times cited : (8)
|
|
References (14)
|
